However, a series of 47 patients with anal carcinoma treated with CRT using IHC to determine p16 expression reported an association of p16 positivity with better 4-year PFS (52.5% vs. 25.0%, p = 0.01) on univariate analysis. Here, CDKN2A is linked to anal carcinoma.